NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, detailing continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted subsequent to the quarter and additional applications targeting MPox and smallpox.
The announcement highlights NanoViricides’ commitment to addressing multiple viral disease targets with NV-387, a nanoviricide drug candidate designed to treat a range of infections including RSV, COVID-19, Long COVID, Influenza, MPox, smallpox, and measles. The company’s lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop for respiratory viral infections as well as poxvirus and measles infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NanoViricides has also developed NV-CoV-2, a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, and NV-CoV-2-R, which encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already US FDA approved, its drug candidate encapsulating remdesivir is likely to be an approvable drug if safety is comparable. Remdesivir is developed by Gilead. The company has developed both drug candidates independently.
The company’s platform technology is based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if initial research is successful.
The path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in the lab will lead to successful clinical trials or a successful pharmaceutical product.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and view the full press release at https://ibn.fm/osO0q.
